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Abstract
Background: Metastatic bone disease is a frequent cause of morbidity in patients with advanced breast cancer, but the role
of the bone mineral hydroxyapatite (HA) in this process remains unclear. We have developed a novel mineralized 3-D tumor
model and have employed this culture system to systematically investigate the pro-metastatic role of HA under
physiologically relevant conditions in vitro.
Methodology/Principal Findings: MDA-MB231 breast cancer cells were cultured within non-mineralized or mineralized
polymeric scaffolds fabricated by a gas foaming-particulate leaching technique. Tumor cell adhesion, proliferation, and
secretion of pro-osteoclastic interleukin-8 (IL-8) was increased in mineralized tumor models as compared to non-mineralized
tumor models, and IL-8 secretion was more pronounced for bone-specific MDA-MB231 subpopulations relative to lung-
specific breast cancer cells. These differences were pathologically significant as conditioned media collected from
mineralized tumor models promoted osteoclastogenesis in an IL-8 dependent manner. Finally, drug testing and signaling
studies with transforming growth factor beta (TGFb) confirmed the clinical relevance of our culture system and revealed
that breast cancer cell behavior is broadly affected by HA.
Conclusions/Significance: Our results indicate that HA promotes features associated with the neoplastic and metastatic
growth of breast carcinoma cells in bone and that IL-8 may play an important role in this process. The developed
mineralized tumor models may help to reveal the underlying cellular and molecular mechanisms that may ultimately enable
more efficacious therapy of patients with advanced breast cancer.
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Introduction
Bone metastasis, the spread of tumor cells to the skeleton, is
a frequent cause of morbidity and mortality in patients with
advanced cancers. Seventy-percent of breast cancer patients with
advanced disease develop bone metastases [1], which lead to
severe bone pain, pathological fractures, hypercalcaemia, and
nerve compression [2–4]. These debilitating skeletal events are a
consequence of secondary tumor formation and pathological bone
remodeling of predominantly osteolytic character [2].
While organ-specific patterns of metastatic colonization are
often mediated by site-specific metastasis signatures [5], micro-
environmental conditions in the bone are implicated in the
pathogenesis of metastatic breast cancer. More specifically,
mammary tumor cells localized within bone up-regulate expres-
sion of growth factors and cytokines that stimulate osteoclasto-
genesis and inhibit osteoblast differentiation relative to the same
cells located in soft tissue sites [6–8]. This process not only
promotes pathological bone resorption, but also leads to the
release of morphogens that further stimulate metastatic tumor
growth and exacerbate the imbalance between bone formation
and resorption.
A variety of growth factors and cytokines drive the vicious cycle
of bone metastasis by increasing tumor progression and patho-
logical bone remodeling. For example, vascular endothelial growth
factor (VEGF) stimulates the formation of new blood vessels and
regulates apoptosis and differentiation of tumor cells and
osteoblasts [9,10]. Additionally, parathyroid hormone related
protein (PTHrP) and interleukin-11 (IL-11) enhance bone
metastasis through activation of osteoclastogenesis [2,6,11–13]
and interleukin-8 (IL-8) may be equally important because of its
pro-angiogenic, pro-migratory, and osteoclastogenic activities
[7,14–20]. Whether or not specific bone microenvironmental
conditions play a role in regulating the signaling by these pro-
metastatic factors, however, remains unclear.
The bone extracellular matrix (ECM) is a composite material
that consists of an inorganic mineral phase dispersed throughout
an organic matrix of collagen. The inorganic component of bone
is primarily composed of the mineral hydroxyapatite (HA), a
crystalline calcium phosphate phase with the molecular formula
Ca5(PO4)3(OH) [21]. While HA is noted for its role in imbuing
bone with exceptional tissue stiffness and serving as a reservoir of
ions (i.e., Ca
2+ and PO4
32), it also represents a bioactive material
that modulates the behavior of both normal and transformed cells
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bone metastasis remain unclear.
Three-dimensional (3-D) polymeric scaffolds represent highly
innovative tools for recreating tumor microenvironmental condi-
tions in culture [24–27]. Compared to conventional 2-D cultures,
tumor cells maintained in 3-D scaffold-based tumor models exhibit
characteristics that are more representative of their behavior in vivo
[25,26]. We therefore engineered a novel, mineralized 3-D tumor
model to investigate the impact of HA on bone cancer metastasis.
This system allowed us to examine various stages of secondary
tumor growth within bone microenvironments (i.e., initial
colonization and subsequent tumor progression, osteolytic capa-
bility) under well-defined and pathologically relevant conditions in
vitro. Our findings indicate for the first time that HA plays a critical
role in controlling directing the osteolytic phenotype of breast
cancer bone metastasis, underscoring the importance of this
mineralized 3-D model system for the study of tumor behavior in
bone.
Results
Physicochemical Characterization of Scaffolds
Scaffold characterization was performed to determine the
physicochemical properties of the developed matrices. Energy
dispersive spectroscopy (EDS) analysis indicated that HA was
available for cellular interactions at the porous surface of the
mineralized scaffolds, while non-mineralized control scaffolds
contained undetectable amounts of calcium or phosphate
(Fig. 1A). Additionally, microCT analysis confirmed uniform
distribution of HA throughout the mineralized scaffolds, whereas
no X-ray absorption was detected for non-mineralized control
scaffolds (Fig. 1B). Not surprisingly, mineralized scaffolds exhibited
compressive moduli that were 2-fold higher than for non-
mineralized control scaffolds (data not shown). These differences
were related to the presence of HA as opposed to alterations in the
microarchitecture, as mineralized and non-mineralized control
scaffolds exhibited similar wall thicknesses (mineralized scaffolds:
58627 mm, non-mineralized scaffolds: 50630 mm) and pore
diameters (mineralized scaffolds: 4326106 mm, non-mineralized
scaffolds: 4516123 mm) (Fig. 1C,D).
Mineralized Scaffolds Promote MDA-MB231 Adhesion
and Proliferation
The ability of HA to affect breast cancer cell colonization and
tumor growth within the bone microenvironment was next
assessed. Relative to non-mineralized scaffolds MDA-MB231 cells
displayed greater penetration into the center of the mineralized
scaffolds and increased adhesion onto HA-containing surfaces, as
indicated by von Kossa staining (Fig. 2A). Quantification of
seeding efficiency confirmed increased adhesion of tumor cells into
mineralized scaffolds (Fig. 2B). These differences were likely
related to increased adsorption of adhesion proteins because
Western Blot analysis showed that fibronectin was more readily
adsorbed onto mineralized scaffolds as compared to non-
mineralized scaffolds (Fig. 2C). Furthermore, blockade of fibro-
nectin-binding integrins with soluble arginine-glycine-aspartic acid
(RGD) peptides decreased initial adhesion into mineralized
Figure 1. Physicochemical characterization of scaffolds. (A) HA in biomineralized scaffolds is available for cellular interactions as EDS analysis
indicates Ca and P at the porous surface of the scaffolds, while no mineral was detected for non-mineralized control scaffolds. (B) MicroCT scans
indicate that HA is uniformly distributed throughout biomineralized scaffolds, but was not present non-mineralized control scaffolds. (C)
Incorporation of HA did not alter the scaffold microarchitecture relative to non-mineralized control scaffolds as indicated by visualization via
brightfield microscopy. Scale bars represent 2 mm. (D) Image analysis of high-resolution brightfield microscopy images indicates that pore size and
polymer wall thickness are similar for both biomineralized and non-mineralized scaffolds.
doi:10.1371/journal.pone.0008849.g001
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of MDA-MB231 cells was also increased in the presence of HA,
as cell numbers increased in mineralized scaffolds relative to
control scaffolds (Fig. 3A). Similarly, MCF-7 cells exhibited a 20%
increase in proliferation in mineralized scaffolds (data not shown)
verifying the relevance of our findings with a second cell type. In
agreement with these results, von Kossa and live/dead staining of
the different MDA-MB231 tumor models indicated enhanced
Figure 2. Effect of HA on breast cancer cell adhesion. (A) Analysis of von Kossa stained histological cross-sections indicates that MDA-MB231
cells (stained red) penetrate into the center of mineralized scaffolds (HA stained black), while this is not the case for non-mineralized control scaffolds.
Arrows and asterisks indicate representative scaffold walls and pores, respectively. Scale bars represent 200 mm. (B) MDA-MB231 breast cancer cells
adhere more efficiently to mineralized scaffolds than non-mineralized scaffolds (**p,0.01), and pre-incubation of MDA-MB231 cells with RGD peptide
inhibits enhanced adhesion to mineralized scaffolds (**p,0.01). Error bars are small where not visible. (C) Fibronectin adsorption within the polymer
scaffold is increased in mineralized scaffolds (lane 2) relative to non-mineralized scaffolds (lane 1) as indicated by Western Blot analysis of scaffold
lysates.
doi:10.1371/journal.pone.0008849.g002
Figure 3. Effect of HA on 3-D tumor tissue formation. (A) Quantification of DNA indicates enhanced proliferation of MDA-MB231 cells within
mineralized scaffolds as compared to non-mineralized scaffolds. (B) Analysis of von Kossa stained histological cross-sections revealed that 5 days after
seeding, coherent tissue begins to form in mineralized scaffolds but not non-mineralized scaffolds (MDA-MB-231 cells stained red, HA stained black).
Scale bars represent 50 mm. (C) Live and dead staining with calcein (green) and propidium iodide (red), respectively, shows increased cell number and
tissue formation into pores of mineralized scaffolds relative to control scaffolds. White scale bars represent 100 mm.
doi:10.1371/journal.pone.0008849.g003
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culture (Fig. 3B,C).
Bone Mineral Promotes Tumor-Mediated Osteoclast
Differentiation and Activity
To assess a potential role of HA in the osteolytic phenotype of
bone metastases, osteoclastogenesis was evaluated in response to
conditioned media. Breast cancer cells cultured within 3-D non-
mineralized scaffolds increased osteoclastogenesis as compared to
control media that was not exposed to tumor cells and media
collected from 2-D cultures (data not shown), but a much more
dramatic effect was detected for mineralized tumor models
(Fig. 4A,B). More specifically, media from mineralized tumor
models increased osteoclast differentiation by 65% with respect to
media from non-mineralized scaffold cultures and this effect was
comparable to media supplemented with pro-osteoclastic receptor
activator for nuclear factor kB ligand (RANKL) (Fig. 4B). To
ensure that tumor-derived soluble factors in the mineralized
culture media, and not soluble products of the scaffold itself (e.g.,
Ca
2+,P O 4
32), were directing osteoclast differentiation, we
cultured RAW 264.7 in cell-free scaffold-incubated media and
found no differential effects on osteoclastogenesis relative to
control media (data not shown). Accordingly, no detectable
amounts of Ca
2+ and PO4
32 were measured in media collected
Figure 4. Osteoclastogenesis in response to conditioned media. (A) Conditioned media collected from mineralized tumor models increased
RAW 264.7 osteoclastogenesis relative to conditioned media collected from non-mineralized tumor models as revealed by TRAP staining of large
multinucleated cells. (B) Quantification of TRAP+ cells indicated that culture media collected from mineralized scaffold cultures (MIN+) promoted RAW
264.7 osteoclastogenesis relative to control media (cDMEM) and media collected from non-mineralized scaffold cultures (MIN-) in a manner that was
similar to osteoclastic RANKL. Asterisks [*p,0.05, **p,0.01] and pound signs [#p,0.05, ##p,0.01] indicate statistical significance with respect to
‘cDMEM’ and ‘MIN-’, respectively. (C) Conditioned media collected from mineralized models (MIN+) enhances the resorptive activity of RAW 264.7
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more, the detected differences in osteoclastogenesis were not due
to altered cell proliferation due to similar cell numbers in all tested
conditions (data not shown). Evaluation of osteoclast resorptive
activity [28] confirmed our results by revealing significantly higher
free Ca
2+ concentrations in response to media collected from
mineralized tumor models exceeding even the osteolytic potential
mediated by 50 ng/mL RANKL (Fig. 4C).
Bone Mineral Enhances Tumor-Mediated
Osteoclastogenesis through Enhanced Secretion of IL-8
The ability of HA to modulate the molecular interplay involved
in tumor-mediated bone osteolysis was next tested by examin-
ing VEGF, PTHrP, IL-11, and IL-8 as specific examples of
tumorigenic and pro-osteoclastic factors. While VEGF and IL-11
secretion by MDA-MB231 cells were not affected by the scaffold
type (Fig. 5A) and PTHrP was secreted at undetectable levels
(,0.3 pM) from either mineralized or non-mineralized tumor
models (data not shown), IL-8 secretion was increased by 38% in
mineralized scaffolds HA (Fig 5A). Similarly, MCF-7 cells secreted
40% more IL-8 when cultured within mineralized scaffolds as
compared to non-mineralized scaffolds (data not shown). These
differences were attributed to the inherent bioactivity of HA
rather than the different mechanical stiffness of the matrices (non-
mineralized scaffolds: 0.5 MPa, mineralized scaffolds: 1.1 MPa), as
scaffolds with lower (50% HA) and higher HA content (200% HA)
and thus lower (0.7 MPa) and higher elastic modulus (2.1 MPa)
exhibited similar effects on breast cancer cell proliferation and IL-
Figure 5. Osteoclastogenesis in response to HA-dependent IL-8 signaling. (A) Tumor cells cultured within mineralized scaffolds up-
regulated secretion of IL-8 relative to culture within non-mineralized control scaffolds, while no effect was detected for VEGF and IL-11 secretion
(*p,0.05). Error bars for IL-11 are large due to low IL-11 secretion. (B) Blockade of IL-8 signaling by addition of a neutralizing antibody inhibited the
pro-osteoclastic effect of conditioned media collected from mineralized tumors (MIN+) to levels comparable to non-mineralized cultures (MIN-)
(*p,0.05). (C) Transwell assays with conditioned media indicate that tumor cells cultured within mineralized scaffolds (MIN+) increase the motility of
RAW 264.7 relative to all other conditions. Inhibition with a function blocking antibody suggested that this effect was IL-8 dependent. (D)
Colorimetric analysis of Ca-release indicates that IL-8 neutralization in media collected from mineralized tumor models (Ab/MIN+) results in a much
more pronounced decrease in osteoclast activity as compared to media collected from non-mineralized scaffold cultures (Ab/MIN-). (E) Micrographs
of osteoclast-mediated pit formation on bone mineral surface in the presence of conditioned media from mineralized tumor models with and
without IL-8 antibody. Scale bars represent 200 mm. (F) Quantification of pit formation in response to the different media in the presence and
absence of functional IL-8 signaling.
doi:10.1371/journal.pone.0008849.g005
Mineralized Tumor Models
PLoS ONE | www.plosone.org 5 January 2010 | Volume 5 | Issue 1 | e88498 secretion (data not shown). IL-8 up-regulation mediated pro-
osteoclastic effects, because inhibition of this signaling by an IL-8
neutralizing antibody yielded similar numbers of osteoclasts as
media collected from non-mineralized scaffolds (Fig. 5B).
Directed migration may be important to the fusion of RAW
264.7 cells to multinucleated, differentiated osteoclasts, and we
hypothesized that IL-8 may play a role in this process.
Conditioned media collected from mineralized tumor models
induced RAW 264.7 migration more significantly relative to
media collected from non-mineralized scaffold cultures or media
supplemented with 50 ng/mL RANKL. Blockade of IL-8 signal-
ing dramatically reduced motility to levels comparable with
cDMEM control media (Fig. 5C). Finally, IL-8 inhibition more
dramatically reduced the resorptive activity of RAW 264.7 cells
cultured within media from mineralized tumor models relative to
media collected from non-mineralized tumor models (Fig. 5D-F).
Clinical Relevance of 3-D Mineralized Tumor Models
To verify that HA affects breast cancer cell behavior in a
clinically relevant manner we evaluated IL-8 secretion in site-
specific metastatic populations of MDA-MB231. Specifically, we
utilized bone and lung metastatic breast cells (established by Dr.
Massague ´ [5,12,29–31]) to assess whether these cells secrete
different amounts of IL-8, and if these levels were altered due to
HA presence. In conventional 2-D culture, IL-8 secretion was
68% higher in the bone-specific subline (1833) as compared to
parental MDA-MB231, while cells of the lung-specific subline
(4175), secreted 80% less IL-8 than the parental cell line (Fig. 6A).
Interestingly, 1833 cells exhibited a dramatic increase (5.5-fold) in
IL-8 secretion in response to HA as compared to parental and
lung-specific MDA-MB231 cells (,2-fold) (Fig. 6B) elevating the
total concentration of IL-8 in the bone-like microenvironment 3-
fold and 6-fold relative to parental and lung-specific MDA-MB231
cells, respectively.
Next, we tested the effect of TGFb1, an important pro-
metastatic factor of the bone metastasis microenvironment, on
osteolytic factor secretion. TGFb1 has been reported to up-
regulate IL-8 [32] and we detected increased IL-8 secretion
in response to TGFb1 in non-mineralized cultures, but surpris-
ingly not in mineralized tumor models (Fig. 6C). Interestingly,
we noticed a different trend when analyzing the effect of TGFb1
on IL-11 secretion. While MDA-MB231 cells in non-mineralized
scaffolds increased their IL-11 secretion by nearly 10-fold,
we detected a greater than 20-fold increase in IL-11 secretion
when these same cells were cultured in mineralized scaffolds
(Fig. 6D).
As bisphosphonates are the standard of care of bone metastatic
breast cancer patients, we also evaluated the therapeutic efficacy of
ibandronate in our culture system. Breast cancer cells exhibited
increased susceptibility to ibandronate in mineralized scaffolds
compared to non-mineralized scaffolds both during administration
of the drug (dosed interval), and after the drug was removed from
the culture medium (undosed interval) (Fig. 6E, F). The switch
between dosed and undosed intervals mimicked clinical treatments
in which bisphosphonates are administered intravenously every 3–
4 weeks (ZOMETA [package insert]. Stein, Switzerland: Novartis
Pharmaceuticals Corp; 2004). These differences were likely
associated with binding of ibandronate to HA as tumor cell
responsiveness was only detected in mineralized scaffolds pre-
incubated with the drug prior to seeding. Importantly, addition of
ibandronate to 2-D cultures and pre-cultured 3-D tumor models
did not yield changes in tumor cell proliferation or death (data not
shown).
Discussion
By integrating biomaterials and tissue engineering strategies, we
have developed a novel, mineralized 3-D tumor model and have
employed this culture system to systematically investigate the pro-
metastatic role of HA under pathologically relevant conditions in
vitro. The results of our study indicate for the first time that
HA controls critical aspects of breast cancer bone metastasis by
directing mammary tumor cells towards a phenotype that
promotes secondary tumor growth and bone destruction and
regulates drug responsiveness.
Our data suggest that cellular interactions with HA are involved
in the colonization and proliferation of breast cancer cells within
the bone microenvironment and that RGD-containing fibronectin
plays a role in this process. This possible relationship is supported
by other studies, which have demonstrated that stromal cell
adhesion to HA is mediated by RGD-containing proteins [33,34]
and that a truncated version of fibronectin can block breast cancer
growth and metastasis in vivo [35]. Accordingly, HA promoted
tumor tissue formation within the biomimetic tumor models in our
studies and this effect was likely due to the integrated effects of
increased adhesion and proliferation. Typically, secondary tumor
formation within the bone microenvironment is considered a
function of bone resorption because the degrading bone mineral
matrix releases bioactive ions and growth factors critical to the
proliferation of both normal and transformed cells [4,11,36,37].
Our data suggest that not only soluble, but also insoluble cues
inherent to the inorganic component of the bone mineral matrix
regulate the metastatic growth of breast cancer cells within bone.
Tumor-derived soluble factors shift the balance between
bone formation and bone degradation towards osteolysis
[2,4,7,11,16,31,36], and our results indicate that HA is strongly
implicated in this process. To identify a potential molecular
mediator that may be involved in these effects, we investigated the
secretion of a number of growth factors and cytokines that are
pivotal to bone metastasis. While VEGF, PTHrP, and IL-11, all of
which are critical regulators of tumor angiogenesis [26,38] and
osteoclast resorption [2,11–13,36], were not affected by the
presence of HA, IL-8 secretion increased under these conditions.
IL-8 promotes tumorigenesis through inflammatory and pro-
angiogenic effects, but increasing evidence additionally implicates
IL-8 as a pro-osteoclastic factor [7,16,39]. Our data support this
concept and additionally suggest that HA increases the pro-
osteolytic secretion of IL-8 independent of TGFb. Essentially our
data imply that tumor cells closely associated with the bone matrix
may utilize HA-dependent up-regulation of IL-8, while cells
located in the center of the tumor (i.e., those not in direct contact
with HA) may depend on TGFb signaling to increase IL-8
secretion. HA may mediate its effects via activation of IL-8 related
signaling pathways that may play a role in ruffled-border
formation and subsequent bone degradation [40,41]. Our finding
that bone-specific MDA-MB231 cells dramatically increase IL-8
concentrations in the bone microenvironment (both inherently
and in response to HA) with respect to parental or lung-specific
MDA-MB231 cells provides further evidence of the clinical
relevance of IL-8 in regulating breast cancer bone metastasis.
HA may mediate the pro-metastatic effects reported in our
studies through a variety of mechanisms. Differences in protein
adsorption may support the initial colonization of tumor cells
extravasated from blood vessels into the bone microenvironment.
Changes in protein adsorption may, in turn, alter the engagement
of integrins, which is implicated in IL-8 dependent tumor growth
[26]. Differences in cell signaling may therefore not only be related
to quantitative differences in protein adsorption as detected in our
Mineralized Tumor Models
PLoS ONE | www.plosone.org 6 January 2010 | Volume 5 | Issue 1 | e8849Figure 6. Clinical relevance of 3-D mineralized tumor models. (A) 1833 bone-metastatic MDA-MB231 cells secrete more IL-8 than parental
and 4175 lung-metastatic cells in 2-D culture. (B) Mineralized scaffold culture increases IL-8 secretion for all MDA-MB231 populations, but this
response is significantly increased in bone-metastatic cells as compared to parental and lung-metastatic cells (**p,0.01, p,0.05). (C) TGFb1 up-
regulates IL-8 secretion in non-mineralized, but not mineralized 3-D cultures of MDA-MB231. (D) In contrast, TGFb1 increases IL-11 secretion more
significantly in mineralized than non-mineralized cultures (p,0.05). (E) Tumor cells cultured within mineralized scaffolds exhibit increased growth
suppression in response to ibandronate both when directly exposed to the drug in the dosed interval (days 1–3) and after the drug was removed
during the undosed interval (days 3–5). (F) Live/dead staining with calcein (green) and propidium iodide (red) confirmed increased cell death in
response to ibandronate in mineralized cultures relative to non-mineralized cultures. Scale bars represent 100 mm.
doi:10.1371/journal.pone.0008849.g006
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protein interactions [42]. Additionally, the presence of HA may
stimulate rises in extracellular Ca
2+ concentrations, which may
affect cancer cell behavior [43]. However, HA is not highly soluble
in the absence of strongly acidic conditions, and, accordingly, we
did not detect elevated Ca
2+ concentrations in media collected
from mineralized scaffolds. Finally, HA confers the bone ECM
with enhanced mechanical stiffness, and physical forces dictate the
behavior of normal and transformed cells [44–47]. Based on
our data, changes in breast cancer cell behavior were influenced
by the inherent bioactivity of HA rather than enhanced sub-
strate stiffness. These results do not exclude the possibility that
mechanical stiffness influences bone metastasis over a different
range of elastic moduli. Not only tissue stiffness, but heightened
interstitial pressure (e.g., due to dysfunctional tumor vasculature)
may be affecting bone metastasis in vivo [45]. Although interstitial
pressure was not affected in our tumor models, it will be possible
to model these effects in the future to provide an integrated
understanding of how the many cues in the microenvironment are
synergistically promoting cancer cell colonization and growth.
We have identified that the osteoclastogenic signaling of IL-8 is
regulated by HA, but it should be noted that the presence of bone
mineral may more broadly affect bone metastasis. For example,
HA could alter tumor cell secretion of osteopontin and osteocalcin,
two factors that regulate bone cell signaling and have a strong
affinity for HA [34,48–51]. Considering the complexity of the
bone microenvironment, it will also be important to take into
account the contributions of other bone cells such as osteoblasts
and osteocytes. These cells release factors that enable tumor cells
to promote osteoclastogenesis [2,6] and this capability may be
altered by HA. Specifically, osteoblasts secrete TGFb1i na
manner that depends on the specific bone characteristics [52], and
that may promote bone resorption via increasing IL-11 secretion
[11–13,31,53,54]. Our findings now additionally suggest that
cancer cell response to TGFb1 is regulated by material
interactions with HA. Future studies, integrating HA with 3-D
co-culture of multiple bone cell types will help to further reveal the
underlying signaling.
Bisphosphonates inhibit osteoclast activation by binding to
mineralized surfaces [2,36], and in our culture system, tumor cell
response to ibandronate was increased in the presence of HA.
These results agree with previous in vivo studies in which
ibandronate treatment decreased MDA-MB231 tumor burden at
the bony site, but not in the mammary fat pad [55]. Our
observation that ibandronate halts tumor cell proliferation even
after removal of the drug from the culture medium could further
explain why breast cancer patients treated with bisphosphonates
have increased disease-free survival and a significantly reduced risk
of disease progression [56]. We saw no effect of ibandronate on the
breast cancer cells in 2-D or in pre-cultured 3-D models with
existing tissue formation, supporting our contention that drug
efficacy is due to the effects of HA binding. Collectively, our data
suggest that bisphosphonates bind to and integrate with mineral-
ized surfaces to deter disease progression and cellular growth at the
bony site.
In conclusion, HA induces secondary tumor growth and IL-8
secretion by breast cancer cells, providing a molecular mechanism
by which the mineral matrix of the bone microenvironment
regulates the pathological bone remodeling associated with breast
cancer bone metastasis. Directly targeting HA as an integral
component of the bone mineral matrix may not represent a viable
option for therapy. However, HA functions may be explored for
improved treatments with bisphosphonates. Tissue-engineered
tumor models will enable studies that will lead to an improved
understanding of the molecular mechanisms by which HA
regulates bone metastasis and current treatment strategies. This
information will be critical to the identification of novel and
specific therapeutic targets that will permit the improved therapy
of patients with advanced breast cancer.
Materials and Methods
Cell Culture
Human MDA-MB231 [5,26,30,36] (ATCC), bone-metastatic
(1833) and lung-metastatic (4175) MDA-MB231 subpopulations
[30,31] (kindly provided by Dr. Joan Massague), MCF-7 [8,25,36]
(ATCC), and murine monocytic RAW 264.7 [57–59] cells
(ATCC) were routinely maintained in complete DMEM
(cDMEM) (i.e., DMEM (Invitrogen) supplemented with 10% fetal
bovine serum [FBS, from Tissue Culture Biologicals] and 1%
penicillin/streptomycin [PS, from Invitrogen]), under standard
cell culture conditions (37uC, 5% CO2).
Scaffold Fabrication
Porous mineralized scaffolds, composed of poly(lactide-co-
glycolide) (PLG) and hydroxyapatite (HA), were fabricated by a
modified gas forming/particulate leaching method [60]. Briefly,
scaffolds were prepared with PLG particles (Lakeshore Biomate-
rials; average diameter=250 mm), PLG microspheres (formed
through a double emulsion process, average diameter=5–50 mm),
HA particles (Sigma, average diameter of 200 nm confirmed with
transmission electron microscopy), and sodium chloride particles
(sieved to a diameter of 250–400 mm, J.T. Baker). A total of 8 mg
of polymer, 8 mg of HA nanoparticles, and 152 mg of NaCl was
used and resulted in final scaffold dimensions of 8.5 mm diameter
by 1 mm thickness after cold-pressing with a Carver Press (Fred S.
Carver). Following high-pressure immersion in carbon dioxide gas
and polymer foaming in a non-stirred pressure vessel (Parr
Instruments), the scaffolds were leached in de-ionized water for
24 hours to remove NaCl porogen particles. Non-mineralized
PLG scaffolds, which were HA-free, were also fabricated, as were
mineralized scaffolds with varying amounts of HA (1:2, 1:4, 2:1
mass ratio with PLG). Prior to cell culture, scaffolds were sterilized
by submersion in 70% ethanol for 30 minutes followed by 5
washes in sterile PBS.
Scaffold Characterization
Scanning electron microscopy (SEM) (Leica 440) and light
microscopy (Observer.Z1, Zeiss) were used to characterize the
microarchitecture and porosity of scaffolds. Energy dispersive
spectroscopy (EDS) (Leica 440) was employed to provide
elemental analysis of scaffolds, including determination of surface
presentation of HA in mineralized scaffolds. For SEM and EDS,
scaffolds were sputter-coated with gold-palladium to reduce
surface charge buildup (Denton Desk II). Scaffolds were tested
with MicroCT (GE Healthcare, eXplore CT120) for further
microarchitectural analysis and to ensure uniform distribution of
HA in mineralized scaffolds. Dynamic mechanical analysis (TA
Instruments Q800) was used to determine the compressive moduli
of the scaffolds.
Western Blot Analysis
Unseeded scaffolds were incubated in cDMEM for 30 minutes,
allowing serum proteins to adsorb. Subsequently, the adsorbed
proteins were released from the scaffolds by mechanically
disintegrating the polymer matrices in a solution of RIPA buffer
(Sigma), protease inhibitor cocktail (Sigma), and PMSF (Sigma).
Following centrifugation, the resulting scaffold lysates were
Mineralized Tumor Models
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(BioRad). The membrane was incubated overnight with a
rabbit anti-human fibronectin (Sigma) antibody. The membrane
was then washed and incubated with a species-specific HRP-
conjugated secondary antibody (Novus Biologicals), followed by
ECL detection (Amersham Biosciences).
Development and Characterization of 3-D Mineralized
Tumor Models
1.5 million breast cancer cells suspended in 30 mLc D M E M
were seeded into each scaffold and maintained under dynamic
culture conditions on an orbital shaker at 37uCa n d5 %C O 2
for up to 10 days. In some cases, the culture medium was
supplemented with 200 pM of recombinant human TGFb1
(R&D) or 1 mM ibandronate (Sigma) based on dose dependency
studies [12,29,55]. Live/Dead assay was performed with calcein/
propidium iodide (Invitrogen) staining and visualization on an
Epi-fluorescence microscope (Observer.Z1, Zeiss). Cell adhesion
was determined by quantifying the number of non-adhered cells
30 min after scaffold seeding using a cell counter (Beckman-
Coulter). Blockade of RGD-binding integrins was performed by
incubating the cells with 20 mg/mL of soluble RGD (Sigma) for
30 min prior to seeding. To measure cell proliferation, tumor
cell-seeded constructs were washed in PBS and lysed in Caron’s
buffer by sonication. Following centrifugation the DNA content
in the supernatant was quantified through fluorescent Hoechst
Assay (Invitrogen). For histological analysis tumor constructs
were fixed in 10% formaldehyde and embedded in paraffin
for sectioning and staining (H&E, von Kossa) according to
established protocols.
Analysis of Conditioned Media
Prior to each time point, breast cancer cell seeded-scaffolds were
transferred to fresh culture plates, and media was changed to
DMEM/1% FBS. Conditioned media were harvested after
24 hours for analysis. VEGF, IL-11, and IL-8 ELISAs (R&D)
were performed on these samples according to manufacturer’s
instructions, while PTHrP secretion was measured using a two-site
immunoradiometric assay (Beckman Coulter). Protein secretion
was normalized to DNA content as determined by fluorimetric
Hoechst Assay. Scaffold-conditioned control media (i.e. media
incubated with unseeded scaffolds) was also analyzed for calcium
and phosphate ion concentration by atomic absorption.
Osteoclastogenic Response
TRAP stain. RAW 264.7 monocytes were seeded in tissue
culture plates and cultured in tumor-conditioned media collected
from mineralized and non-mineralized 3-D tumor models for
5 days with or without 10 mg/mL of IL-8 neutralizing antibody
(R&D). cDMEM and scaffold-conditioned control media (i.e.
media incubated with unseeded scaffolds) were used as a negative
controls, while cDMEM supplemented with RANKL (Sigma)
served as a positive control [61]. RANKL was added at a
concentration of 50 ng/mL, which has previously been shown
to induce osteoclastogenesis [7]. To quantify osteoclastogenesis,
a tartrate-resistant acid phosphatase (TRAP) staining kit (Sigma)
was used according to manufacturer’s instructions in conjunc-
tion with image analysis of TRAP positive, multinucleated
cells using AxioVision software (Zeiss). Similar cell numbers
between the different experimental conditions were verified with
an AlamarBlue assay (AbD Serotec Ltd) as indicated by the
manufacturer.
Migration assay. RAW 264.7 monocytes were seeded on
top of collagen-coated polycarbonate tissue culture inserts (8 mm
pore diameter, Nunc), which were placed into well plates with
tumor-conditioned media or control media as specified above.
After 8 h of incubation, a cotton swab was used to remove cells
from the top of the inserts, while cells that had migrated through
the polycarbonate membrane towards the conditioned media,
were stained with DAPI. Stained inserts were then imaged, and
the number of migrated cells was analyzed by AxioVision (Zeiss)
image analysis.
Osteoclast activity assays. RAW 264.7 monocytes were
seeded onto Corning Bone Cell Assay Surfaces [28] (kindly
provided by Corning Life Sciences) and cultured in the culture
media specified above. Osteoclast activity was determined by
quantifying calcium release from the Bone Cell Assay Surfaces
into culture media due to osteoclast-mediated resorption. Spe-
cifically, calcium release was measured by colorimetric detection
of complexation of free calcium ions to o-cresolphthalein
complexone (Sigma). Additionally, osteoclast activity was de-
termined by light microscopic quantification of resorption pit area
on the Bone Cell Assay Surface plates.
Statistical Analysis
One-way ANOVA and Student’s t-test were used to determine
statistical significance, and p,0.05 is indicated by (*) while p,0.01
is indicated by (**) in all figures. For all experiments, sample size is
greater than or equal to 3 for each condition. Data are presented
as average; error bars indicate standard deviation.
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